Tytgat Institute

anje-te-veldeAnje te Velde

Anje te Velde is principle investigator at the Tytgat Institute for Liver and Intestinal Research. She studied medical biology at the Free University in Amsterdam and obtained her PhD on a thesis entitled ‘Human monocytes in the cytokine network’ at the University of Amsterdam and the Netherlands Cancer Institute in 1990. In 1991, she started her work at the Academic Medical Center (AMC) where she was one of the initiators of the development of the bioartificial liver (BAL). In 1996 she switched her research interest to the field of inflammatory bowel diseases.
Te Velde investigates immunological aspects of inflammatory bowel diseases using experimental models and human material. She also participates in the education of medical biology and medical students. Her main interest is to unravel the pathophysiology of IBD. The understanding of the pathophysiologic mechanisms involves research of genetic alterations, environmental factors and a dysregulated mucosal immune response to the gut microbiota. Together with our collaborators we study the effect of functional foods, modulated T cells, small molecules and effective peptides in experimental colitis models, the role of microRNAs and fibroblast-like cells, and the immune response in IBD patients. In 2015 she received a grant from the ECCO to study the DNA methylation profile in IBD fibroblasts. In addition she collaborates with the paediatric IBD department in the DIKI project (Data Integration in Kids with IBD) to unravel subtypes in childhood IBD. This translational research is the work of different PhD students. Recently, we implemented mouse colonoscopy which allows longer follow-up of diseased animals without need to sacrifice them. Te Velde is a member of the scientific core group of the Immunowell foundation (www.immunowell.com) aiming to determine the status of a healthy immune system.

wouter-de-jongeWouter de Jonge

Wouter de Jonge (UU-Biomedical Sciences) was trained at Columbia University NY, University of Amsterdam (AMC) and the University of Maastricht and received his PhD in 2001, on the regulation of amino acid metabolism in the gut. During that time he became interested in neurogastroenterology, in particular in relation to gut innate immunology and host defence. He did a postdoc at Oxford University on macrophage physiology. He was/is funded by an EU FP7 Marie Curie grant (2006), a FEBS award (2006) and VIDI grant (2008), and several other non-personal grants. In 2009, he was appointed PI in the newly formed Tytgat Institute and laboratory of Gastroenterology and Hepatology, AMC (website: www.gut-research.com). Currently, his research focusses on neurogastroenterology and mucosal immunity. The gut immune cells have a high degree of tolerance towards commensal bacteria, and this is essential to prevent inflammatory disease. Research in de Jonge’s group aims to unravel this tolerant nature of mucosal immunity, and the dysregulation thereof in human GI disease. In addition, he is coordinating a joint EU project on epigenetics in mucosal immune cells in the context of IBD, in alliance with industry partner GSK (website: www.epimac.eu).
De Jonge aims to optimize the close merge between gastroenterologists, basic researchers and industrial partners from Life Science industry at the AMC setting. His group has long lasting collaborations with industrial partners in several projects involving pre-clinical and clinical evaluation of pipeline assets for human GI disease. His group studies gut inflammatory diseases (IBDs) as well as motility disorders (ileus, IBS).
The current research themes and directions of the group include intestinal immunity and nutrition, stress in relation to mucosal immunity, and nutrition and epithelial barrier function during health and disease. Correspondence on collaboration, or information of any kind is welcomed at: w.j.dejonge@amc.nl

medew-manonManon Wildenberg

Manon Wildenberg finished her PhD in Immunology at the Erasmus MC in 2008. Afterwards she started her research on Inflammatory Bowel Diseases with a post-doc in gastroenterology at the LUMC. She joined the AMC in 2011, and became a staff member at the Tytgat Institute in 2015. The main research focus in the Wildenberg group is the mechanism of action of current and new therapies in IBD, with the dual aim of developing new medications and optimizing the use of available drugs. Specific research topics include 1) the role of various IBD associated genetic variations in the behavior of (myeloid) immune cells and wound healing, 2) using IBD associated genetic variation in the prediction of response to therapy and 3) the mechanism of action of anti-TNF and other drugs on a cellular level. In addition, in close collaboration with the department of Surgery, the group studies the role of mesenteric immunity in the pathology of Crohn’s disease and possible consequences for surgical approaches. Research funding sources include the European Crohn and Colitis Organization (ECCO), Health Holland/TKI and Netherlands Organisation for Health Research and Development (ZonMW).

hergen-spitsHergen Spits

During his career Spits has performed both academic and industry research at world-class institutions: the Netherlands Cancer Institute (NKI) as Head of the Department of Immunology, the Academic Medical Centre where he is Professor of Cell Biology, Schering Plough France, the DNAX Research Institute in Palo Alto, CA and Genentech in South San Francisco, CA. As a Senior Director of Immunology managing 70 scientists at Genentech, one of the largest biotech companies in the world, Spits was responsible for the discovery of novel drugs for treatment of immunity mediated inflammatory diseases (IMID). Spits returned to the AMC in July 2009 with the goal to develop a new frontier research program in translational immunology focused on IMIDs such as inflammatory bowel disease (IBD). While current interventions ameliorate disease symptoms, they do not provide a cure, and there is significant unmet medical need. Successful discovery and development of more effective IMID therapies depends on a better understanding of the underlying mechanisms of disease. Spits investigates how proinflammatory cells proliferate unchecked, and how the body’s own mechanisms might be enlisted to control inflammation.